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erogeneous aetiology. Despite this heterogeneity, HCCs have been
classiﬁed into distinct subtypes based on candidate approaches
or global screening methods [1–6]. Moreover, whole genome
sequencing of HCCs and putative secondary growths have deﬁned
genetic changes associated with intrahepatic metastasis [7].
However, the identiﬁcation of driver mutations in HCC is still a
challenging task [8]. Mouse models are valuable tools to identify
the contribution of deﬁned genetic changes to HCC formation. As
recently reviewed by Gen-Sheng Feng, controversial results have
been obtained in mice for several candidate genes that seemed to
display both, tumour-promoting and tumour-suppressive activi-
ties [9]. These controversial ﬁndings are reconciled by the fact
that gene activities can inﬂuence HCC formation by two mecha-
nisms: (1) a candidate gene is required for tumour cell prolifera-
tion or survival (oncogenic function); (2) a candidate gene is
essential for survival of hepatocytes, thereby preventing chronic
liver injury and regeneration (anti-oncogenic function). These
mechanisms might operate in all tissues with high regenerative
capacity. Consequently, chronic liver injury induced by ablation
of an essential candidate gene could drive formation of HCCs with
speciﬁc mutations that override tumour cell-autonomous
requirements for the candidate gene. This dual mechanism exac-
erbates our interpretations of cell-autonomous gene functions in
HCC formation when corresponding mouse models differ from
control groups with respect to chronic liver injury. Moreover,
many models do not reﬂect the human aetiology of HCC, which
is associated with inﬂammation, chronic liver damage, and liver
ﬁbrosis.Journal of Hepatology 20
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Open access under CC BY-NC-ND license.In this issue of the Journal of Hepatology, Meng et al. employed
mice lacking the farnesoid X receptor (FXR/) to investigate
oncogenic functions of type II interferon (IFNc) signalling in
HCC formation [10]. FXR/ mice represent a model of HCC
induced by metabolic dysfunction and the authors have recently
demonstrated that this model can recapitulate several aspects of
human HCC [11]. They showed that FXR downregulation in
human HCCs was mediated by cytokines that interfered with
HNF1a (hepatocyte nuclear factor 1a) chromatin binding and pro-
posed multiple mechanisms on how loss of FXR could support
hepatocarcinogenesis [11]. FXR is required for hepatocyte survival
thereby preventing chronic liver injury but also regulates expres-
sion of target genes, such as SHP (small heterodimer partner), that
are implicated in hepatocarcinogenesis. Moreover, chronic liver
injury in FXR/ mice led to inﬁltration of macrophages and ele-
vated hepatic expression of inﬂammatory cytokines which
induced abnormal hepatocyte proliferation, a driving force for
expansion of transformed cells [11]. One of the most prominently
upregulated cytokines in FXR/ mice was IFNc [12]. This cyto-
kine, however, suppresses formation of various tumour types by
cell-autonomous and non-cell-autonomous mechanisms. IFNc
stimulates immune surveillance functions of the innate immune
system and can induce expression of immunomodulatory factors
such as MHC (major histocompatibility complex) molecules in
tumour cells. Moreover, IFNc signalling interferes with tumour
cell proliferation and promotes apoptosis. Many of these functions
are mediated by the transcription factor STAT1 (signal transducer
and activator of transcription 1). Consistent with the anti-
proliferative and pro-apoptotic activities of IFNc/STAT1 signals,
tumour cells try to escape from this pathway and acquire resis-
tance by different means (downregulation of IFNc receptors; dele-
tion of the genomic IFNc locus; promoter methylation of STAT1 or
other factors implicated in IFNc signalling which makes tumour
cells refractory to IFNc signals) [13]. The tumour-suppressive
activity of IFNc/STAT1 is partly due to mutually interfering inter-
actions between STAT1 and the closely related transcription factor
STAT3 (signal transducer and activator of transcription 3). In con-
trast to STAT1, STAT3 is considered to promote formation of many
tumours including HCC. However, administration of the carcino-
gen DEN (diethylnitrosamine) in mice with conditional inactiva-
tion of STAT3 in the liver has provided controversial results with
two studies suggesting an oncogenic activity [14,15] and one
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Fig. 1. Functions of IFNc signalling in hepatocellular carcinoma. (A) The major sources of IFNc in the liver are sinusoidal NK, NKT and T cells, attracted during
inﬂammation and liver injury triggered by different insults. IFNc acts on Kupffer cells and macrophages and promotes production of cytokines such as TNFa. Moreover, NK
cells kill stellate cells and IFNc interferes with TGFb signalling in stellate cells thereby executing antiﬁbrogenic functions. (B) IFNc signalling in hepatocytes is ampliﬁed
during hepatic injury, inﬂammation and ageing via upregulation of IFNc receptor or IFNc ligand expression. IFNc/STAT1 interferes with hepatoprotective and tumour-
promoting activities of STAT3, induces apoptosis of hepatocytes (in synergy with TNFa) via several mechanisms (p53-independent) and promotes cell cycle arrest in an
IRF1/p53/p21-dependent manner. STAT1 and p53 directly interact with each other and co-regulate expression of p21. Moreover, STAT1 can increase p53 protein levels via
repression of Mdm2 expression and other molecular mechanisms. The pro-apoptotic activity of STAT1 is modulated by NFjB, a hepatoprotective transcription factor that is
also activated by IFNc. These molecular mechanisms integrate anti-oncogenic activities of IFNc/STAT1. (C) Upon hepatocyte transformation, IFNc signalling is compromised
and IL-6/STAT3 signalling is enhanced leading to STAT3 activation and reduced STAT1 activity. The latter results in release from cell cycle arrest and reduced IFNc/STAT1-
induced apoptosis. Moreover, STAT1-dependent mechanisms for stabilization of p53 are ablated. These molecular events might contribute to hepatocyte transformation in
a tumour cell-autonomous manner. Moreover, IFNc signalling prevents accumulation of ROS (partially via NFjB) and activation of JNK thereby executing hepatoprotective
functions. Consequently, loss of IFNc leads to necrotic liver damage, a condition that promotes HCC formation especially when additional insults such as genotoxic or
metabolic stress (FXR ablation) are present.
JOURNAL OF HEPATOLOGYhave performed a similar experiment and found signiﬁcant reduc-
tion of DEN-induced HCC formation in the absence of STAT3
(unpublished) suggesting an oncogenic function. The mutual
interaction between STAT1 and STAT3 became particularly
apparentwhen STAT1 or STAT3 activities were selectively ablated.
Deletion of STAT1 switched the pro-apoptotic and anti-
proliferative activities of IFNs to survival and proliferation signals
in various cell types. This functional switch was at least in part
due to aberrant activation of STAT3 by IFN signals that occurred
only in the absence of STAT1. In contrast, STAT1 was activated
by glycoprotein gp130-inducing signals when STAT3 was ablated.
Consequently, STAT3-deﬁcient ﬁbroblasts responded to IL-6
(interleukin-6) with substantial STAT1 activation that resulted
in unusual IL-6-mediated activation of IFN responsive genes
[17]. The molecular mechanisms that underlie the reciprocal
inﬂuence of STAT1 and STAT3 activation include competition for
common cytokine receptors, the implication of SOCS (suppressorJournal of Hepatology 201of cytokine) proteins and the mutual inactivation of STATs by
sequestration into STAT1:STAT3 heterodimer complexes [18].
The report by Meng et al. shed new light on the role of IFNc
and the mutual interplay of STAT transcription factors in hepato-
protection and HCC formation [10]. Abolishing IFNc signalling led
to increased hepatic damage and tumour load in livers of IFNc/,
IFNc/ FXR/ double-deﬁcient and IFNc/ mice treated with
DEN [10]. These experiments provide new insights into
tumour-suppressive activities of IFNc signals that seem to oper-
ate not only in tumour cells but also through hepatoprotective
mechanisms (Fig. 1). The hepatoprotective activity of IFNc was
age-dependent since old IFNc/ mice displayed hepatic inﬂam-
mation and elevated levels of liver damage parameters that were
not obvious in young mice. Interestingly, levels of IFNc increased
in humans and mice during ageing indicating that an age-
dependent physiologic mechanism co-ordinately regulates IFNc
levels and IFNc responsiveness of hepatocytes.2 vol. 57 j 940–942 941
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Increased tumour load in double-deﬁcient IFNc/ FXR/
mice and IFNc/ mice treated with DEN might result from aggra-
vated chronic liver damage and regeneration. Moreover, aggra-
vated liver damage was accompanied by several molecular
changes that promote HCC formation including STAT3 activation,
reduction of NFjB activity, decreased p53 expression and ele-
vated activation of JNK (Jun aminoterminal kinase) [10]. STAT3
activation might be due to the aforementioned mutual interac-
tion between IFNc/STAT1 and IL-6/STAT3 signalling pathways,
which was further demonstrated in vitro. Activation of JNK, med-
iated by reactive oxygen species (ROS) and blunted NFjB activa-
tion, could contribute to p53 downregulation via its target
protein c-Jun, a transcription factor known to repress expression
of p53 in hepatocarcinogenesis [19]. In this regard, JNK could act
synergistically with known IFNc/STAT1-dependent mechanisms
for p53 regulation (Fig. 1). However, these mechanisms seemed
to operate predominantly during HCC initiation because p53
expression was not affected in established tumours of IFNc/
FXR/ mice. Recently, Katz et al. have investigated p53 functions
in HCC. They demonstrated formation of HCCs with stem cell-like
characteristics (Alb+ and K19+) in aged mice with conditional
ablation of p53 in hepatocytes [20]. It would be interesting to
investigate whether the short window of p53 loss during tumour
initiation is sufﬁcient to promote formation of bilineal HCCs with
stem cell-like characteristics in IFNc/ FXR/ mice.
In summary, the study by Meng et al. has proposed an impor-
tant IFNc-dependent cellular and molecular network between
innate immune cells and hepatocytes. This network could pro-
vide protection from liver damage and HCC formation during
viral hepatitis or autoimmune hepatitis that are associated with
attraction of several hematopoietic producers of IFNc. Paradoxi-
cally, gain and loss of IFNc signalling lead to hepatocyte death
but only loss of IFNc promotes HCC formation. It remains to be
investigated how the concerted action with additional IFNc
responses such as cell cycle arrest modulates anti-oncogenic
activities of IFNc-induced apoptosis.Conﬂict of interest
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